Cartesian Therapeutics (RNAC) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $6.58, +3.79% vs the prior close of $6.34.
- Volume 86.80K shares, 0.7x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
RNAC jumps 3.8% to $6.58. Closed at $6.58, +3.79% vs the prior close of $6.34. Day range $6.39–$6.78, opened at $6.39.
RNAC daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — RNAC jumps 3.8% to $6.58
- Closed at $6.58, +3.79% vs the prior close of $6.34. Day range $6.39–$6.78, opened at $6.39.
- Volume was 86.80K shares, 0.7x its 50-day average of 131.21K.
- Price is -21.0% vs its 50-day average ($8.33) and -14.6% vs its 200-day average ($7.70).
- 52-week range $5.60–$11.00; today's close sits at 18% of that range, 40.2% below the 52-week high.
Oct 14, 2026 — RNAC slides 3.5% to $6.34, a 3-month low, 3 down days in a row
- Closed at $6.34, -3.50% vs the prior close of $6.57. Day range $6.33–$6.69, opened at $6.55.
- Volume was 173.40K shares, 1.3x its 50-day average of 133.70K.
- Price is -24.2% vs its 50-day average ($8.37) and -17.7% vs its 200-day average ($7.70).
- 52-week range $5.60–$11.00; today's close sits at 14% of that range, 42.4% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — RNAC slides 6.0% to $6.57, a 3-month low
- Closed at $6.57, -6.01% vs the prior close of $6.99. Day range $6.57–$7.02, opened at $6.98.
- Volume was 218.60K shares, 1.7x its 50-day average of 131.56K.
- Price is -21.8% vs its 50-day average ($8.40) and -14.7% vs its 200-day average ($7.70).
- 52-week range $5.60–$11.00; today's close sits at 18% of that range, 40.3% below the 52-week high.
Oct 12, 2026 — RNAC dips 0.9% to $6.99
- Closed at $6.99, -0.92% vs the prior close of $7.05. Day range $6.95–$7.15, opened at $7.03.
- Volume was 107.80K shares, 0.8x its 50-day average of 132.21K.
- Price is -17.1% vs its 50-day average ($8.43) and -9.3% vs its 200-day average ($7.71).
- 52-week range $5.60–$11.00; today's close sits at 26% of that range, 36.5% below the 52-week high.
Oct 9, 2026 — RNAC jumps 3.4% to $7.05
- Closed at $7.05, +3.45% vs the prior close of $6.82. Day range $6.85–$7.16, opened at $6.87.
- Volume was 114.50K shares, 0.9x its 50-day average of 131.89K.
- Price is -16.5% vs its 50-day average ($8.45) and -8.4% vs its 200-day average ($7.70).
- 52-week range $5.60–$11.00; today's close sits at 27% of that range, 35.9% below the 52-week high.
Oct 8, 2026 — RNAC rises 2.1% to $6.82
- Closed at $6.82, +2.10% vs the prior close of $6.68. Day range $6.50–$6.82, opened at $6.68.
- Volume was 214.40K shares, 1.6x its 50-day average of 130.98K.
- Price is -19.4% vs its 50-day average ($8.46) and -11.4% vs its 200-day average ($7.70).
- 52-week range $5.60–$11.00; today's close sits at 23% of that range, 38.0% below the 52-week high.
Oct 7, 2026 — RNAC dips 1.0% to $6.68, a 3-month low, 3 down days in a row
- Closed at $6.68, -1.04% vs the prior close of $6.75. Day range $6.60–$6.84, opened at $6.70.
- Volume was 86.40K shares, 0.7x its 50-day average of 131.38K.
- Price is -21.1% vs its 50-day average ($8.47) and -13.3% vs its 200-day average ($7.70).
- 52-week range $5.60–$11.00; today's close sits at 20% of that range, 39.3% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — RNAC slides 5.5% to $6.75, a 3-month low
- Closed at $6.75, -5.46% vs the prior close of $7.14. Day range $6.75–$7.23, opened at $7.15.
- Volume was 171.20K shares, 1.3x its 50-day average of 129.54K.
- Price is -20.5% vs its 50-day average ($8.49) and -12.4% vs its 200-day average ($7.71).
- 52-week range $5.60–$11.00; today's close sits at 21% of that range, 38.6% below the 52-week high.
Oct 5, 2026 — RNAC dips 3.0% to $7.14, a 3-month low
- Closed at $7.14, -2.99% vs the prior close of $7.36. Day range $7.11–$7.43, opened at $7.36.
- Volume was 226.20K shares, 1.8x its 50-day average of 127.88K.
- Price is -16.1% vs its 50-day average ($8.51) and -7.4% vs its 200-day average ($7.71).
- 52-week range $5.60–$11.00; today's close sits at 29% of that range, 35.1% below the 52-week high.
Oct 2, 2026 — RNAC rises 1.9% to $7.36
- Closed at $7.36, +1.94% vs the prior close of $7.22. Day range $7.29–$8.05, opened at $7.32.
- Volume was 200.40K shares, 1.6x its 50-day average of 126.68K.
- Price is -13.7% vs its 50-day average ($8.53) and -4.6% vs its 200-day average ($7.72).
- 52-week range $5.60–$11.00; today's close sits at 33% of that range, 33.1% below the 52-week high.
RNAC latest news & SEC filings
Every SEC filing by or about RNAC in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $0)
- Net income: $15.77M (prior year $15.89M) (-0.7% vs Jun 30, 2025)
- Diluted EPS: $0.46 (prior year $0.50) (-8.0% vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 22, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade RNAC
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: Apr 30, 2026, Mar 9, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.42% (largest 6.0%).
- Liquidity: about 156.25K shares (≈$1.03M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $6.58 vs a range of $5.60–$11.00 (18% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 1 open-market buys, 3 sales; latest: Blaine Davis sold 10,591 shares on Jan 6, 2026.
- Latest filings: 8-K Sep 29, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Share count: 30.26M shares outstanding (Jul 31, 2026), +16.4% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
RNAC market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 6.39 | 6.78 | 6.39 | 6.58 | 86.80K |
| Oct 14, 2026 | 6.55 | 6.69 | 6.33 | 6.34 | 173.40K |
| Oct 13, 2026 | 6.98 | 7.02 | 6.57 | 6.57 | 218.60K |
| Oct 12, 2026 | 7.03 | 7.15 | 6.95 | 6.99 | 107.80K |
| Oct 9, 2026 | 6.87 | 7.16 | 6.85 | 7.05 | 114.50K |
| Oct 8, 2026 | 6.68 | 6.82 | 6.50 | 6.82 | 214.40K |
| Oct 7, 2026 | 6.70 | 6.84 | 6.60 | 6.68 | 86.40K |
| Oct 6, 2026 | 7.15 | 7.23 | 6.75 | 6.75 | 171.20K |
| Oct 5, 2026 | 7.36 | 7.43 | 7.11 | 7.14 | 226.20K |
| Oct 2, 2026 | 7.32 | 8.05 | 7.29 | 7.36 | 200.40K |
| Oct 1, 2026 | 7.16 | 7.44 | 7.15 | 7.22 | 175.70K |
| Sep 30, 2026 | 7.31 | 7.57 | 7.15 | 7.21 | 166.90K |
| Sep 29, 2026 | 7.28 | 7.56 | 7.10 | 7.24 | 157.80K |
| Sep 28, 2026 | 7.32 | 7.34 | 7.01 | 7.21 | 109.10K |
| Sep 25, 2026 | 7.60 | 7.60 | 7.31 | 7.41 | 158.60K |
| Sep 24, 2026 | 7.86 | 7.87 | 7.41 | 7.62 | 205.80K |
| Sep 23, 2026 | 8.05 | 8.15 | 7.65 | 7.87 | 117.00K |
| Sep 22, 2026 | 8.03 | 8.32 | 7.95 | 8.08 | 161.70K |
| Sep 21, 2026 | 8.11 | 8.23 | 7.75 | 7.94 | 61.40K |
| Sep 18, 2026 | 7.88 | 8.26 | 7.66 | 8.03 | 211.40K |
About Cartesian Therapeutics
Cartesian Therapeutics (RNAC) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in FREDERICK, MD. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1453687.
RNAC board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Timothy C Barabe | Director | Jan 6, 2026 |
| Adrian Ion Bot | Director | Dec 18, 2025 |
| Carsten Brunn | President and CEO | Jan 8, 2026 |
| Nishan M Desilva | Director | Jan 6, 2026 |
| Kemal Malik | Director | Jan 6, 2026 |
| Timothy A Springer | Director | Jan 6, 2026 |
| Michael Singer | Director | Mar 13, 2026 |
| Patrick J Zenner | Director | Jan 6, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Carsten Brunn | President and CEO | Jan 8, 2026 |
| Blaine Davis | Chief Financial Officer | Jan 8, 2026 |
| Emily English | Chief Operations Officer | Jan 6, 2026 |
| Milos Miljkovic | Chief Medical Officer | Jan 8, 2026 |
| June Ann Seymour | Chief Accounting Officer | Jan 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jan 6, 2026 | Blaine Davis | Sale | 10,591 | $6.82 |
| Jan 6, 2026 | Milos Miljkovic | Sale | 3,573 | $6.82 |
| Jan 6, 2026 | Carsten Brunn | Sale | 23,766 | $6.82 |
| Dec 4, 2025 | Timothy C Barabe | Buy | 30,000 | $6.86 |
RNAC financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $400.00K | $-130.30M | -5.02 | $-73.94M |
| Dec 31, 2024 | $38.27M | $-77.42M | -4.49 | $-23.67M |
| Dec 31, 2023 | $26.00M | $-219.71M | -49.76 | $-51.16M |
| Dec 31, 2022 | $110.78M | $35.38M | 0.10 | $-31.63M |
| Dec 31, 2021 | $85.08M | $-25.69M | -0.22 | $-60.38M |
Latest balance sheet: total assets $318.63M, total liabilities $443.85M, cash $147.61M (as of Jun 30, 2026).
RNAC earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $8.76 |
| Apr 30, 2026 | 8-K Item 2.02 (results) | $6.22 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $9.02 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $7.55 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $10.54 |
| May 8, 2025 | 8-K Item 2.02 (results) | $10.42 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $16.61 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $20.78 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
| Mar 7, 2024 | 8-K Item 2.02 (results) | — |
| Aug 17, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on RNAC
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.